Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

por McChalicher, Christopher, Abdulaziz, Ahmad, Zhou, S Steve, Lombardo, Mary-Jane, Hasson, Brooke, Auniņš, John G, McGovern, Barbara H, Ege, David S
Publicado 2022

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes

por Ford, Christopher, Henn, Matthew, Bryant, Jessica, Diao, Liyang, Wortman, Jennifer, Tomlinson, Amelia, Litcofsky, Kevin, Bernardo, Patricia, McGovern, Barbara, Aunins, John G, Cook, David N, Trucksis, Michele
Publicado 2018

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool

por McChalicher, Christopher W J, Lombardo, Mary-Jane, Khanna, Sahil, McKenzie, Gregory J, Halvorsen, Elizabeth M, Almomani, Sanabel, Schuster, Brian, Hasson, Brooke R, McGovern, Barbara H, Ege, David S, Auniņš, John G
Publicado 2023

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner

por Henn, Matthew, Ford, Christopher, O’Brien, Edward, Wortman, Jennifer, Diao, Liyang, Desjardins, Christopher, Tomlinson, Amelia, Litcofsky, Kevin, Wilcox, Mark, Buckley, Anthony, Bernardo, Patricia, McGovern, Barbara, Aunins, John G, Cook, David N, Trucksis, Michele
Publicado 2018

A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis

por Henn, Matthew R., O’Brien, Edward J., Diao, Liyang, Feagan, Brian G., Sandborn, William J., Huttenhower, Curtis, Wortman, Jennifer R., McGovern, Barbara H., Wang-Weigand, Sherry, Lichter, David I., Chafee, Meghan, Ford, Christopher B., Bernardo, Patricia, Zhao, Peng, Simmons, Sheri, Tomlinson, Amelia D., Cook, David N., Pomerantz, Roger J., Misra, Bharat K., Auninš, John G., Trucksis, Michele
Publicado 2021

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

por McGovern, Barbara H, Ford, Christopher B, Henn, Matthew R, Pardi, Darrell S, Khanna, Sahil, Hohmann, Elizabeth L, O’Brien, Edward J, Desjardins, Christopher A, Bernardo, Patricia, Wortman, Jennifer R, Lombardo, Mary-Jane, Litcofsky, Kevin D, Winkler, Jonathan A, McChalicher, Christopher W J, Li, Sunny S, Tomlinson, Amelia D, Nandakumar, Madhumitha, Cook, David N, Pomerantz, Roger J, Auninš, John G, Trucksis, Michele
Publicado 2020